Table 1.
Baseline characteristics of participants included in analyses of grade 2 or greater CNS adverse events after being randomly assigned to efavirenz-containing regimens.
| Cases (n=167) |
Controls (n=653) |
Total (N=820) |
||
|---|---|---|---|---|
| Parent study, n (%) | ACTG384 | 28 (13.9) | 173 (86.1) | 201 |
| A5095 | 63 (34.4) | 120 (65.6) | 183 | |
| A5142 | 15 (10.1) | 133 (89.9) | 148 | |
| A5202 | 61 (21.2) | 227 (78.8) | 288 | |
| Sex, n (%) | Male | 156 (16.4) | 539 (77.6) | 695 |
| Female | 11 (8.8) | 114 (91.2) | 125 | |
| Race or ethnic group, n (%) | White Non-Hispanic | 81 (22.8) | 274 (77.2) | 355 |
| Black Non-Hispanic | 53 (20.1) | 211 (79.9) | 264 | |
| Hispanic | 26 (14.1) | 158 (85.9) | 184 | |
| Asian | 2 (25.0) | 6 (75.0) | 8 | |
| Native American | 3 (42.9) | 4 (57.1) | 7 | |
| Multiracial | 1 (100) | 0 (0) | 1 | |
| Unknown | 1 (100) | 0 (0) | 1 | |
| Age, Median (IQR) | 38 (31, 45) | 37 (31, 45) | 37 (31, 45) |